AMULET IDE: New Research Compares WatchMan and Amulet Devices Providing New Evidence

Recently, at the TCT Congress results from the SWISS-APERO study comparing Watchman and Amulet devices were presented. Now, a new study, Amulet IDE—published in Circulation—, compared both devices on a large number of patients.

AMULET Die: Un nuevo estudio compara los dispositivos Watchman y Amulet y arroja nueva evidencia

Amulet IDE was designed to evaluate the safety and efficacy of dual-seal mechanism device Amulet compared with the Watchman (a widely used tool in clinical practice).

In this sense, the Amulet device was non-inferior in terms of safety and efficacy to prevent stroke in patients with nonvalvular atrial fibrillation compared with the Watchman device. Atrial appendage occlusion was superior with Amulet—a result also observed in SWISS-APERO.

In this study, 1878 patients with nonvalvular atrial fibrillation and at high risk of stroke were randomized to receive either device. The primary safety endpoint was a composite of procedure-related complications, all-cause mortality, or major bleeding.

The efficacy endpoint was a composite of ischemic stroke or systemic embolism at 18 months. Atrial appendage seal at 45 days was also considered.

In terms of safety, Amulet proved to be non-inferior to Watchman (14.5% vs. 14.7%; p < 0.001).


Read also: TCT 2021 | SWISS-APERO: Difference in Leaks between the Amulet and the Watchman.


However, results were similar for major bleeding and death (10.6% vs. 10.0%, and 3.9% vs. 5.1%, respectively).

Procedure-related complications (pericardial effusion and device embolization) were higher with Amulet (4.5% vs. 2.5%).

Conclusion

The Amulet atrial appendage occluder device was non-inferior in terms of safety and efficacy for stroke prevention in patients with nonvalvular atrial fibrillation. Peri-procedural complications were higher with Amulet, but decreased with increased operator experience.

amulet-die

Original Title: Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE).

Reference: Dhanunjaya Lakkireddy et al. Circulation. 2021 Nov 9;144(19):1543-1552. doi: 10.1161/CIRCULATIONAHA.121.057063.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...